New oral treatment shows significant promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome

Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome, according to new research.